Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica

Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

NCT01211834 ·Status: COMPLETED ·Phase: PHASE3

Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed

NCT05533125 ·Status: COMPLETED ·Phase: PHASE3

Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis

NCT02885818 ·Status: COMPLETED

Evaluation of the Condition of Rheumatoid Arthritis After Treatment

NCT02157012 ·Status: UNKNOWN ·Phase: PHASE4

A Rheumatoid Arthritis Study in Participants

NCT01202760 ·Status: COMPLETED ·Phase: PHASE3

Pharmaco Kinetic Variability of Infliximab in Rheumatoid Arthritis

NCT00840957 ·Status: COMPLETED

Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis

NCT00213564 ·Status: COMPLETED

Study on the Safety of Abatacept in Relapsing Polychondritis

NCT01272856 ·Status: COMPLETED ·Phase: PHASE1

Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes

NCT02469753 ·Status: COMPLETED ·Phase: PHASE3

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

NCT03241108 ·Status: COMPLETED ·Phase: PHASE2

Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis

NCT06933134 ·Status: RECRUITING

Identification of Factors Associated With the Occurrence of Severe Forms of COVID-19 Infection in Patients With Inflammatory Rheumatism or Autoimmune Diseases

NCT05026892 ·Status: UNKNOWN

Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients

NCT00124449 ·Status: COMPLETED ·Phase: PHASE2

Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)

NCT02304354 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants

NCT00760669 ·Status: COMPLETED

Vaccination Against SARS-Cov2 (COVID-19) in Chronic Inflammatory Rheumatism and Factors Determining Its Decision.

NCT04970550 ·Status: COMPLETED

Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica

NCT01423591 ·Status: UNKNOWN ·Phase: PHASE3

A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs

NCT01034397 ·Status: COMPLETED ·Phase: PHASE4

JAK-i on RA B-lymphocytes Tolerance and Disease Resolution Through JAK Signaling In Rheumatoid Arthritis

NCT05754112 ·Status: UNKNOWN

Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

NCT03227419 ·Status: UNKNOWN ·Phase: PHASE4

Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients

NCT01633346 ·Status: COMPLETED

Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients

NCT02547493 ·Status: COMPLETED ·Phase: NA

A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis

NCT00380744 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Rheumatologic Adverse Events and Cancer Immunotherapy

NCT04791150 ·Status: UNKNOWN ·Phase: NA

Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

NCT02963402 ·Status: COMPLETED